公开(公告)号：EP1756036A1

公开(公告)日：2007-02-28

申请号：EP05733516.8

申请日：2005-04-12

申请人： KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  JE IL Pharmaceutical Co., Ltd. ,  Korea Research Institute of Bioscience and Biotechnology ,  CJ Corp.

发明人： CHEON, Hyae Gyeong ,  YOO, Sung-Eun ,  KIM, Sung Soo ,  YANG, Sung-Don ,  KIM, Kwang-Rok ,  RHEE, Sang Dal ,  AHN, Jin Hee ,  KANG, Seung Kyu ,  JUNG, Won Hoon ,  PARK, Sung Dae ,  KIM, Nam Gee ,  KIM, Sun Mee ,  MO, Kil Woong ,  LEE, Jae Mok ,  KANG, Hye Jung ,  LEE, Koun Ho ,  KIM, Jong Hoon ,  LEE, Jeong-Hyung ,  KIM, Seung Jun

IPC分类号： C07C69/753

CPC分类号： C07D295/088 ,  C07C65/26 ,  C07C69/757 ,  C07C229/50 ,  C07C233/52 ,  C07C255/47 ,  C07C2601/14 ,  C07C2602/08 ,  C07D295/155

摘要： The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.

公开(公告)号：EP1740531A1

公开(公告)日：2007-01-10

申请号：EP05733398.1

申请日：2005-04-13

申请人： KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  Jeil Pharmaceutical Co., Ltd. ,  Korea Research Institute of Bioscience and Biotechnology ,  CJ Corp

发明人： CHEON, Hyae Gyeong ,  YOO, Sung-Eun ,  KIM, Sung Soo ,  YANG, Sung-Don ,  KIM, Kwang-Rok ,  RHEE, Sang Dal ,  AHN, Jin Hee ,  KANG, Seung Kyu ,  JUNG, Won Hoon ,  PARK, Sung Dae ,  KIM, Nam Gee ,  LEE, Jang Hyuk ,  HUH, Sun Chul ,  LEE, Jae Mok ,  SONG, Seog Beom ,  KWON, Soon Ji ,  KIM, Jong H. ,  LEE, Jeong-Hyung ,  KIM, Seung Jun

IPC分类号： C07C251/44

CPC分类号： C07D213/30 ,  C07C291/02 ,  C07C309/66 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2603/74 ,  C07D213/53 ,  C07D233/64 ,  C07D277/24 ,  C07D295/088 ,  C07D295/185 ,  C07D307/54 ,  C07D317/60 ,  C07D317/70 ,  C07D333/24 ,  C07D333/28 ,  C07D417/12

摘要： The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.

摘要翻译： 式（I）的本发明的茚衍生物能够选择性地调节过氧化物酶体增殖物激活受体（PPAR）的活性，引起无副作用，因此它们可用于治疗和预防由PPAR调节的病症， 代谢综合征如糖尿病，肥胖症，动脉硬化，高脂血症，高胰岛素血症和高血压，炎性疾病如骨质疏松症，肝硬化和哮喘以及癌症。

公开(公告)号：EP2740723A2

公开(公告)日：2014-06-11

申请号：EP12763010.1

申请日：2012-03-30

申请人： Korea Research Institute of Chemical Technology

发明人： KIM, Ki Young ,  AHN, Jin Hee ,  KANG, Seung Kyu ,  BAE, Myung Ae ,  AHN, Sung Hoon ,  KIM, Hee Youn ,  JUNG, Won Hoon ,  KANG, Nam Sook ,  RHEE, Sang Dal

IPC分类号： C07C307/06 ,  A61K31/18 ,  A61P3/10

CPC分类号： C07D417/04 ,  A61K31/18 ,  C07C307/10 ,  C07C2603/74 ,  C07D285/10 ,  C07D285/14 ,  C07D285/15 ,  C07D285/16 ,  C07D285/36 ,  C07D417/10 ,  C07D417/12

摘要： Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), and is useful in the treatment of various diseases that are mediated by 11β-HSD1.

公开(公告)号：EP2842938A1

公开(公告)日：2015-03-04

申请号：EP13781273.1

申请日：2013-04-25

申请人： Korea Research Institute of Chemical Technology ,  Handok Pharmaceuticals Co., Ltd.

发明人： AHN, Jin Hee ,  H. S. Pagire ,  RHEE, Sang Dal ,  KIM, Ki Young ,  JUNG, Won Hoon ,  BAE, Myung-Ae ,  SONG, Jin Sook ,  KIM, Kwang-Rok ,  KWAK, Hyun Jung

IPC分类号： C07C233/25 ,  A61K31/16 ,  A61P3/04 ,  A61P1/16

CPC分类号： C07D213/82 ,  A61K31/167 ,  A61K31/216 ,  A61K31/27 ,  A61K31/403 ,  A61K31/415 ,  A61K31/421 ,  A61K45/06 ,  C07B2200/07 ,  C07C237/04 ,  C07C237/12 ,  C07C237/22 ,  C07C271/22 ,  C07C2601/14 ,  C07D209/20 ,  C07D209/42 ,  C07D213/56 ,  C07D231/12 ,  C07D231/14 ,  C07D239/26 ,  C07D261/08 ,  C07D261/10 ,  C07D263/32 ,  C07D263/34 ,  C07D271/06 ,  C07D277/30 ,  C07D277/56 ,  C07D417/12

摘要： The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.

摘要翻译： 本发明涉及一种β-丙氨酸衍生物，其药学上可接受的盐，以及包括该作为活性成分的药物组合物。 新颖的β-丙氨酸衍生物及其药学上可接受的雅丁到本发明的盐可以有效地抑制DGAT1的活性，所有这些是在作为中性脂质的合成的最后步骤中的催化剂的酶，从而可以有效地用作 用于预防或治疗选自肥胖症，血脂异常，脂肪肝，胰岛素抵抗综合征，和肝炎的选择的各种脂质代谢相关的病症的药物组合物。

公开(公告)号：EP2740723B1

公开(公告)日：2017-05-10

申请号：EP12763010.1

申请日：2012-03-30

申请人： Korea Research Institute of Chemical Technology

发明人： KIM, Ki Young ,  AHN, Jin Hee ,  KANG, Seung Kyu ,  BAE, Myung Ae ,  AHN, Sung Hoon ,  KIM, Hee Youn ,  JUNG, Won Hoon ,  KANG, Nam Sook ,  RHEE, Sang Dal

IPC分类号： C07C307/10 ,  A61K31/18 ,  A61P3/10

CPC分类号： C07D417/04 ,  A61K31/18 ,  C07C307/10 ,  C07C2603/74 ,  C07D285/10 ,  C07D285/14 ,  C07D285/15 ,  C07D285/16 ,  C07D285/36 ,  C07D417/10 ,  C07D417/12